Xu and colleagues demonstrated that CD44 depletion in glioblastoma cells is responsible for activating the Hippo pathway, inhibiting tumor growth in vivo and in vitro, as well as sensitizing glioblastoma to temozolomide treatment [85]. This evidence concerns the gene CD44 and neoplasm.